Bayer, Others Settle With U.S. Over Weight

Bayer, Others Settle With U.S. Over Weight

Bayer, others settle with U.S. over weight-loss ads
Flags blow in front of the Bayer AG headquarters in Leverkusen August 9, 2001. Bayer AG and several other smaller companies agreed to pay the U.S. authorities virtually $26 million to settle allegations of false weight-loss promoting claims, the Federal Trade Fee mentioned on... REUTERS/Juergen Schwarz
WASHINGTON Bayer AG and several smaller corporations agreed to pay the U.S. government nearly $26 million to settle allegations of false weight-loss promoting claims, the Federal Trade Commission mentioned on Thursday.
The settlements involve Bayer's One-A-Day WeightSmart multi-vitamin, in addition to the fat burners CortiSlim, TrimSpa and Xenadrine EFX, that are made and offered by other firms.
"You are not going to find weight reduction in a bottle of tablets," FTC Chairman Deborah Platt Majoras instructed reporters. "These advertisements are encouraging consumers to postpone the more durable choices that must be made when one needs to drop some pounds."
Within the case of Bayer, the company pays a $3.2 million civil penalty to settle FTC allegations that adverts for One-A-Day WeightSmart multivitamins violated an earlier company order requiring all well being claims for One-A-Day model vitamins to be supported by scientific evidence.
One-A-Day WeightSmart contains epigallocatechin gallate, a green tea extract, which Bayer ads claimed might help enhance the body's metabolism to control weight, the FTC stated.
In a statement, Bayer said its product offers "safe and efficient nutritional support to those that are watching their weight." The company said it "strongly disagrees" with the FTC's description of the product as weight-loss capsules.
The FTC additionally stated two marketers of eating regimen tablet Xenadrine EFX - RTC Analysis & Growth and Robert Chinery Jr. - pays up to $12.eight million to settle allegations that the product's weight-loss claims have been false and unsubstantiated.
Xenadrine EFX accommodates green tea extract and bitter orange, and advertisements claimed the product was clinically confirmed to trigger rapid and substantial weight reduction.
However, the FTC alleged that in one in every of these studies, subjects taking Xenadrine EFX misplaced a mean of just one.5 kilos over the 10-week study, whereas a control group taking a placebo lost a median of two.5 pounds over the same interval.
The company additionally said that shopper endorsers featured in adverts had been paid up to $20,000 for their appearances after reducing weight with rigorous food plan or train programs.
In one other case, seven entrepreneurs of CortiSlim and CortiStress agreed to pay an $eight.4 million settlement, the FTC said.
Nationwide adverts for CortiSlim falsely claimed it may trigger fast and everlasting weight reduction, whereas CoriStress claimed it might reduce the danger of osteoporosis, obesity, diabetes, Alzheimer's illness, most cancers, and coronary heart illness, the FTC stated. The businesses settling included Window Rock Enterprises Inc. and Infinity Promoting Inc.
Marketers of another weight-reduction plan capsule, TrimSpa, agreed to pay a $1.5 million settlement, the FTC stated.
Advertisements for TrimSpa claimed it triggered speedy and substantial weight loss and that considered one of its elements, Hoodia gordonii, suppressed appetite. In one ad, celeb Anna Nicole Smith claimed to have misplaced sixty nine kilos in eight months by using the diet capsule.
The entrepreneurs involved within the TrimSpa settlement are Goen Technologies Corp., Nutramerica Corp., TrimSpa, Inc., and Alexander Szynalski.
Subsequent In U.S.
EXTRA FROM REUTERS